These data are consistent with detrimental consequences of C5a–C5aR1 activity in neurodegenerative diseases, including AD, and that inhibition of C5a–C5aR1 signaling may slow or prevent the progression of these diseases. This evidence concerns the gene C5AR1 and Alzheimer disease.